Prediabetes assessment and follow-up in older veterans with schizophrenia

American Journal of Geriatric Psychiatry

Volumn 18, Issue 10, 2010, Pages 887-896

  Copeland, Laurel A ^a,b   Parchman, Michael L ^a,b   Zeber, John E ^a,b   Lawrence, Valerie A ^a,b   Downs, John R ^a,b   Miller, Alexander L ^b  

^a South Texas Veterans HCS   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Mortality; prediabetes; schizophrenia; veterans

Indexed keywords

CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; VETERAN;

EID: 77958061109     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181e56cdc     Document Type: Article

References (37)

1. Baptista T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16 (Pubitemid 29309192)
2. Haupt DW, Newcomer JW: Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62(suppl 27):15-26; discussion 40-41
3. Sable JA, Jeste DV: Antipsychotic treatment for late-life schizophrenia. Curr Psychiatry Rep 2002; 4:299-306
4. Nasrallah H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28(suppl 1):83-96
5. Rosack J: FDA to require diabetes warning on antipsychotics. Psychiatric News 2003; 38:1
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272
8. Morrato EH, Newcomer JW, Kamat S, et al: Metabolic screening after the American Diabetes Association's consensus statement on anti-psychotic drugs and diabetes. Diabetes Care 2009; 32:1037-1042
9. American Diabetes Association: Frequently Asked Questions about Pre-Diabetes. 2008 [cited Nov. 22, 2008]; Available at: http://www.diabetes.org/ pre-diabetes/faq.jsp. Accessed May 24, 2010
10. Shimazaki T, Kadowaki T, Ohyama Y, et al: Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl Res 2007; 149:196-204
11. Lorenzo C, Williams K, Hunt KJ, et al: The National Cholesterol Education Program\-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13
12. Liu J, Grundy SM, Wang W, et al: Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007; 153:552-558 (Pubitemid 46440680)
13. Barr EL, Zimmet PZ, Welborn TA, et al: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian
14. Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116:151-157
15. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002; 136:575-581 (Pubitemid 34407041)
16. American Diabetes Association: Total Prevalence of Diabetes and Pre-Diabetes. Available at: http://www.diabetes.org/diabetes-statistics/ prevalence.jsp. Accessed August 2, 2009
17. Lambert TJ, Velakoulis D, Pantelis C: Medical comorbidity in schizophrenia. Med J Aust 2003; 178(suppl):S67-S70
18. Lambert MT, Copeland LA, Sampson N, et al: New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:919-923
19. Copeland LA, Zeber JE, Wang CP, et al: Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilization. BMC Health Serv Res 2009; 9:127
20. Blow FC, McCarthy JF, Valenstein M, et al: Care for Veterans With Psychosis in the VHA, FY02: 4th Annual National Psychosis Registry Report. Ann Arbor, MI, VA National Serious Mental Illness Treatment Research and Evaluation Center [SMITREC], Health Services Research & Development Center of Excellence, 2003
21. Brown S: Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171:502-508
22. Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217
23. Parks J, Svendsen D, Singer P, et al: Morbidity and Mortality in People With Serious Mental Illness. 13th Technical Report. Alexandria, VA, National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2006
24. Hebert PL, Geiss LS, Tierney EF, et al: Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270-277
25. Engelgau MM, Geiss LS, Saaddine JB, et al: The evolving diabetes burden in the United States. Ann Intern Med 2004; 140:945-950
26. Schneeweiss S, Seeger JD, Maclure M, et al: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154:854-864
27. Shen Y, Hendricks A, Zhang S, et al: VHA enrollees' health care coverage and use of care. Med Care Res Rev 2003; 60:253-267
28. Pugh MJ, Copeland LA, Zeber JE, et al: The impact of epilepsy on health status among younger and older adults. Epilepsia 2005; 46:1820-1827
29. Krein SL, Hofer TP, Kerr EA, et al: Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities. Health Serv Res 2002; 37:1159-1180
30. American Diabetes Association: Standards of medical care in diabetes\-2008. Diabetes Care 2008; 31(suppl 1):S12-S54
31. Kilbourne AM, Post EP, Bauer MS, et al: Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord 2007; 102:145-151
32. Kerr EA, Gerzoff RB, Krein SL, et al: Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med 2004; 141:272-281
33. Nutting PA, Rost K, Smith J, et al: Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med 2000; 9:1059-1064
34. Morrato EH, Druss B, Hartung DM, et al: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67:17-24
35. Wolinsky FD, Coe RM, Mosely RR II, et al: Veterans' and nonvet-erans' use of health services. A comparative analysis. Med Care 1985; 23:1358-1371
36. Rosenheck R, Fontana A: Utilization of mental health services by minority veterans of the Vietnam era. J Nerv Ment Dis 1994; 182: 685-691
37. Valenstein M, Copeland LA, Owen R, et al: Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001; 62:545-551